the report of the intramural research programs and make recommendations regarding personnel staffing decisions.

Persons attending FDA's advisory committee meetings are advised that the Agency is not responsible for providing access to electrical outlets.

FDA welcomes the attendance of the public at its advisory committee meetings and will make every effort to accommodate persons with physical disabilities or special needs. If you require special accommodations due to a disability, please contact Donald W. John or Denise Royster at least 7 days in advance of the meeting.

FDA is committed to the orderly conduct of its advisory committee meetings. Please visit our Web site at http://www.fda.gov/AdvisoryCommittees/AboutAdvisoryCommittees/ucm111462.htm for procedures on public conduct during advisory committee meetings.

Notice of this meeting is given under the Federal Advisory Committee Act (5 U.S.C. app. 2).


Jill Hartzler Warner,
Acting Associate Commissioner for Special Medical Programs.

[FR Doc. 2013–07961 Filed 4–4–13; 8:45 am
BILLING CODE 4160–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration
[Docket No. FDA–2013–N–0001]

2013 Medical Countermeasures Initiative Regulatory Science Symposium

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice of meeting.

The Food and Drug Administration (FDA) is announcing the following meeting: 2013 Medical Countermeasures Initiative (MCMi) Regulatory Science Symposium. The symposium is intended to provide a forum for the exchange of ideas for medical countermeasure development, highlight work on regulatory science as it applies to the development and advancement of medical countermeasures, facilitate innovative directions, and inform stakeholders on medical countermeasure-related scientific progress and accomplishments.

Dates and Times: The symposium will be held on May 29 and May 30, 2013, from 9 a.m. to 5 p.m., and on May 31, 2013, from 9 a.m. to 12 noon.

Persons interested in attending the symposium in person or viewing via Webcast must register by May 24, 2013, at 5 p.m. EST.

Location: The symposium will be held at the FDA White Oak Campus, 10903 New Hampshire Ave., Bldg. 31 Conference Center, the Great Room (Rm. 1503), Silver Spring, MD 20993–0002. Entrance for the symposium participants (non-FDA employees) is through Building 1 where routine security check procedures will be performed. For parking and security information, please refer to http://www.fda.gov/AboutFDA/WorkingatFDA/BuildingsandFacilities/WhiteOakCampusInformation/ucm241740.htm.

Contact: Rakesh Raghuvanshi, Office of Counterterrorism and Emerging Threats, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 32, Rm. 4283, Silver Spring, MD 20993, 301–796–4769, Fax: 301–847–8615, email: AskMCMF@dha.hhs.gov.

Registration: If you wish to attend the symposium or view via Webcast, you must register at http://www.fda.gov/medicalcountermeasures by May 24, 2013, at 5 p.m. EST. When registering, you must provide the following information: (1) Your name, (2) title, (3) company or organization (if applicable), (4) mailing address, (5) phone number, and (6) email address.

There is no fee to register for the symposium and registration will be on a first-come, first-served basis. Early registration is recommended because seating is limited.

If you need special accommodations due to a disability, please enter pertinent information in the “Notes” section of the electronic registration form when you register.

Date: April 1, 2013.

Peter Lurie,
Acting Associate Commissioner for Policy and Planning.

[FR Doc. 2013–07893 Filed 4–4–13; 8:45 am
BILLING CODE 4160–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration
[Docket No. FDA–2013–N–0001]

Society of Clinical Research Associates-Food and Drug Administration Clinical Trial Requirements, Regulations, Compliance, and Good Clinical Practice

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice of conference.

SUMMARY: The Food and Drug Administration (FDA) is announcing an educational conference co-sponsored with the Society of Clinical Research Associates (SOCRA). The conference on FDA’s clinical trial requirements is designed to aid the clinical research professional’s understanding of the mission, responsibilities, and authority of FDA and to facilitate interaction with FDA representatives. The program will focus on the relationships among FDA and clinical trial staff, investigators, and institutional review boards (IRBs). Individual FDA representatives will discuss the informed consent process and informed consent documents, and regulations relating to drugs, devices, and biologics, as well as inspections of clinical investigators, IRBs, and research sponsors.

DATES: Date and Time: The conference will be held on May 15 and 16, 2013, from 8 a.m. to 5 p.m.

Location: The conference will be held at the Renaissance Seattle Hotel, 515 Madison St., Seattle, WA 98104.


Registration and Meeting Information: See SOCRA Web site, www.SOCRA.org. http://www.socra.org/html/FDA_Conference.htm. Registrations fees are as follows: $575.00 for SOCRA members; $650.00 for nonmembers (includes membership); $450.00 for Federal Government members; $525.00 for Federal Government nonmembers; FDA employee rate is fee-waived. The registration fee will cover actual expenses including refreshments, lunch, materials, and speaker expenses. If you need special accommodations due to a disability, please contact Jane Kreis (see Contact Person) at least 10 days in advance.

SUPPLEMENTAL INFORMATION: The public workshop helps fulfill the Department of Health and Human Services’ and FDA’s important mission to protect the public health. The workshop will provide those engaged in FDA-regulated (human) clinical trials with information on a number of topics concerning FDA requirements related to informed consent, clinical investigation requirements, institutional review board inspections, electronic record